References
- Shen L-S, Jin X-Y, Wang X-M, Tou L-Z, Huang J. Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Chin Med J. 2020;133(9):1099–1108. doi:https://doi.org/10.1097/CM9.0000000000000745.
- Yin L, Duan -J-J, Bian X-W, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi:https://doi.org/10.1186/s13058-020-01296-5.
- Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clin Cancer Res. 2015;21(7):1688–1698.doi:https://doi.org/10.1158/1078-0432.CCR-14-0432.
- Lehmann BD, Jovanović B, Chen X, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016;11(6):e0157368.doi:https://doi.org/10.1371/journal.pone.0157368.
- Barton VN, D’Amato NC, Gordon MA, et al. Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo. Mol Cancer Ther. 2015;14(3):769–778.doi:https://doi.org/10.1158/1535-7163.MCT-14-0926.
- Zuo T, Wilson P, Cicek AF, Harigopal M. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers. Hum Pathol. 2018;80:239–245. doi:https://doi.org/10.1016/j.humpath.2018.06.003.
- Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen Receptor Expression and Outcomes in Early Breast Cancer: a Systematic Review and Meta-Analysis. JNCI J Natl Cancer Inst. 2014;106(1):djt319–djt319.doi:https://doi.org/10.1093/jnci/djt319.
- Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer. Clin Cancer Res. 2009;15(7):2472–2478.doi:https://doi.org/10.1158/1078-0432.CCR-08-1763.
- Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406.doi:https://doi.org/10.1186/s13058-014-0406-x.
- Liu Y-N, Liu Y, Lee H-J, Hsu Y-H, Chen J-H. Activated Androgen Receptor Downregulates E-Cadherin Gene Expression and Promotes Tumor Metastasis. Mol Cell Biol. 2008;28(23):7096–7108. doi:https://doi.org/10.1128/MCB.00449-08.
- Ahram M, Mustafa E, Zaza R, et al. Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells. Cell Biol Int. 2017;41(12):1345–1355.doi:https://doi.org/10.1002/cbin.10841.
- Ahram M, Bawadi R, Abdullah MS, et al. Involvement of β-catenin in Androgen-induced Mesenchymal Transition of Breast MDA-MB-453 Cancer Cells. Endocr Res. 2021;46(3):114–128.doi:https://doi.org/10.1080/07435800.2021.1895829.
- Ahram M, Mustafa E, Abu Hammad S, et al. The cellular and molecular effects of the androgen receptor agonist, Cl-4AS-1, on breast cancer cells. Endocr Res. 2018;43(3):203–214.doi:https://doi.org/10.1080/07435800.2018.1455105.
- Oram KF, Carver EA, Gridley T. Slug expression during organogenesis in mice. Anat Rec. 2003;271(1):189–191. doi:https://doi.org/10.1002/ar.a.10027.
- Yang J, Weinberg RA. Epithelial-Mesenchymal Transition: at the Crossroads of Development and Tumor Metastasis. Dev Cell. 2008;14(6):818–829. doi:https://doi.org/10.1016/j.devcel.2008.05.009.
- Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–981. doi:https://doi.org/10.1083/jcb.200601018.
- Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer. 2012;12(1):23–38. doi:https://doi.org/10.1038/nrc3169.
- Moody SE, Perez D, Pan TC, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005;8(3):197–209.doi:https://doi.org/10.1016/j.ccr.2005.07.009.
- Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-Mesenchymal Transitions in Development and Disease. Cell. 2009;139(5):871–890. doi:https://doi.org/10.1016/j.cell.2009.11.007.
- Nieto MA, Sargent MG, Wilkinson DG, Cooke J. Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science. 1994;264(5160):835–839. doi:https://doi.org/10.1126/science.7513443.
- Lopez D, Niu G, Huber P, Carter WB. Tumor-induced upregulation of Twist, Snail, and Slug represses the activity of the human VE-cadherin promoter. Arch Biochem Biophys. 2009;482(1–2):77–82. doi:https://doi.org/10.1016/j.abb.2008.11.016.
- O’Connor CM, Adams JU. Essentials of Cell Biology. Cambridge, MA: NPG Education; 2010.
- Nichols AS, Floyd DH, Bruinsma SP, Narzinski K, Baranski TJ. Frizzled receptors signal through G proteins. Cell Signal. 2013;25(6):1468–1475. doi:https://doi.org/10.1016/j.cellsig.2013.03.009.
- Ozanne DM. Androgen Receptor Nuclear Translocation Is Facilitated by the f-Actin Cross-Linking Protein Filamin. Mol Endocrinol. 2000;14(10):1618–1626. doi:https://doi.org/10.1210/me.14.10.1618.
- Cao X, Qin J, Xie Y, et al. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene. 2006;25(26):3719–3734.doi:https://doi.org/10.1038/sj.onc.1209408.
- Wu K, Gore C, Yang L, et al. Slug, a unique Androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol Endocrinol. 2012;26(9):1496–1507.doi:https://doi.org/10.1210/me.2011-1360.
- Jing Y, Cui D, Guo W, et al. Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition. Cancer Lett. 2014;348(1–2):135–145.doi:https://doi.org/10.1016/j.canlet.2014.03.018.
- Rimler A, Jockers R, Lupowitz Z, Sampson SR, Zisapel N. Differential effects of melatonin and its downstream effector PKCalpha on subcellular localization of RGS proteins. J Pineal Res. 2006;40(2):144–152. doi:https://doi.org/10.1111/j.1600-079X.2005.00290.x.
- Hickey TE, Robinson JLL, Carroll JS, Tilley WD. Minireview: the Androgen Receptor in Breast Tissues: growth Inhibitor, Tumor Suppressor, Oncogene? Mol Endocrinol. 2012;26(8):1252–1267. doi:https://doi.org/10.1210/me.2012-1107.
- Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Pushing estrogen receptor around in breast cancer. Endocr Relat Cancer. 2016;23(12):T227–T241. doi:https://doi.org/10.1530/ERC-16-0427.
- Rahim B, O’Regan R. AR Signaling in Breast Cancer. Cancers (Basel). 2017;9(12):21. doi:https://doi.org/10.3390/cancers9030021.
- Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Futur Oncol. 2008;4(1):15–21. doi:https://doi.org/10.2217/14796694.4.1.15.
- Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995;52(5):459–467.doi:https://doi.org/10.1016/0960-0760(95)00005-K.
- Giovannelli P, Di Donato M, Auricchio F, Castoria G, Migliaccio A. Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly. Sci Rep. 2019;9(1):1–14. doi:https://doi.org/10.1038/s41598-019-41016-4.
- Colditz J, Rupf B, Maiwald C, Baniahmad A. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells. Mol Cell Biochem. 2016;421(1–2):139–147. doi:https://doi.org/10.1007/s11010-016-2794-y.
- Voutsadakis I. Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: a Review and in Silico Investigation. J Clin Med. 2016;5(1):11. doi:https://doi.org/10.3390/jcm5010011.
- Urbanucci A, Sahu B, Seppälä J, et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene. 2012;31(17):2153–2163.doi:https://doi.org/10.1038/onc.2011.401.
- Augello M, Burd C, Birbe R, et al. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest. 2013;123(1):493–508.doi:https://doi.org/10.1172/JCI64750DS1.
- Wilson S, Qi J, Filipp FV. Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines. Sci Rep. 2016;6(August):1–15. doi:https://doi.org/10.1038/srep32611.
- Hemavathy K, Guru SC, Harris J, Chen JD, Ip YT. Human Slug Is a Repressor That Localizes to Sites of Active Transcription. Mol Cell Biol. 2000;20(14):5087–5095. doi:https://doi.org/10.1128/mcb.20.14.5087-5095.2000.
- Chen D, Sun Y, Yuan Y, et al. miR-100 Induces Epithelial-Mesenchymal Transition but Suppresses Tumorigenesis, Migration and Invasion. PLoS Genet. 2014;10(2):e1004177.doi:https://doi.org/10.1371/journal.pgen.1004177.
- Pakula H, Xiang D, Li Z. A tale of two signals: AR and WNT in development and tumorigenesis of prostate and mammary gland. Cancers (Basel). 2017;9(2):1–34. doi:https://doi.org/10.3390/cancers9020014.
- Ahram M, Abdullah MS, Mustafa SA, Alsafadi DB, Battah AH. Androgen down‐regulates desmocollin 2 in association with induction of mesenchymal transition of breast MDA‐MB‐453 cancer cells. Cytoskeleton. January 2022. doi:https://doi.org/10.1002/cm.21691.
- Nieto MA, Ryyj H, Jackson RAA, Thiery JPP. Emt: 2016. Cell. 2016;166(1):21–45. doi:https://doi.org/10.1016/j.cell.2016.06.028.
- Saitoh M. Involvement of partial EMT in cancer progression. J Biochem. 2018;164(4):257–264. doi:https://doi.org/10.1093/jb/mvy047.
- Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341–352.doi:https://doi.org/10.1038/s41580-020-0237-9.
- Karaosmanoğlu O, Banerjee S, Sivas H. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells. Cell Oncol. 2018;41(4):439–453. doi:https://doi.org/10.1007/s13402-018-0384-6.
- Leroy P, Mostov KE. Slug Is Required for Cell Survival during Partial Epithelial-Mesenchymal Transition of HGF-induced Tubulogenesis. Margolis B, ed. Mol Biol Cell. 2007;18(5):1943–1952. doi:https://doi.org/10.1091/mbc.e06-09-0823.
- Haensel D, Dai X. Epithelial-to-mesenchymal transition in cutaneous wound healing: where we are and where we are heading. Dev Dyn. 2018;247(3):473–480. doi:https://doi.org/10.1002/dvdy.24561.
- Cacan E. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. J Chemother. 2017;29(3):173–178. doi:https://doi.org/10.1080/1120009X.2016.1277007.
- Wang C, Ye Q, Cao Y, et al. Downregulation of regulator of G protein signaling 2 expression in breast invasive carcinoma of no special type: clinicopathological associations and prognostic relevance. Oncol Lett. November 2017. doi:https://doi.org/10.3892/ol.2017.7351.
- Smalley MJ, Iravani M, Leao M, et al. Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast Cancer Res. 2007;9(6):R85.doi:https://doi.org/10.1186/bcr1834.
- Lyu JH, Park D-W, Huang B, et al. RGS2 Suppresses Breast Cancer Cell Growth via a MCPIP1-Dependent Pathway. J Cell Biochem. 2015;116(2):260–267.doi:https://doi.org/10.1002/jcb.24964.
- Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFβ/TNFα-Mediated Epithelial–Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype. Cancer Res. 2011;71(13):4707–4719. doi:https://doi.org/10.1158/0008-5472.CAN-10-4554.
- Boelte KC, Gordy LE, Joyce S, Thompson MA, Yang L, Lin PC. Rgs2 Mediates Pro-Angiogenic Function of Myeloid Derived Suppressor Cells in the Tumor Microenvironment via Upregulation of MCP-1. PLoS One. 2011;6(4):e18534. doi:https://doi.org/10.1371/journal.pone.0018534.
- Kim H-J, Roh MS, Son CH, et al. Loss of Med1/TRAP220 promotes the invasion and metastasis of human non-small-cell lung cancer cells by modulating the expression of metastasis-related genes. Cancer Lett. 2012;321(2):195–202.doi:https://doi.org/10.1016/j.canlet.2012.02.009.
- Yin H, Wang Y, Chen W, Zhong S, Liu Z, Zhao J. Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC. Gene. 2016;594(1):23–29. doi:https://doi.org/10.1016/j.gene.2016.08.043.
- Kodama T, Newberg JY, Kodama M, et al. Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma. Proc Natl Acad Sci. 2016;113(24):E3384–E3393.doi:https://doi.org/10.1073/pnas.1606876113.
- Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Knockdown of receptor-interacting serine/threonine protein kinase-2 (RIPK2) affects EMT-associated gene expression in human hepatoma cells. Anticancer Res. 2012;32(9):3775–3783. http://www.ncbi.nlm.nih.gov/pubmed/22993319.
- Linder A, Hagberg Thulin M, Damber J-E, Welén K. Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression. Sci Rep. 2018;8(1):17259. doi:https://doi.org/10.1038/s41598-018-35332-4.
- Wu C, Tuo Y, Hu G, Luo J. miR-183-5p Aggravates Breast Cancer Development via Mediation of RGS2. Comput Math Methods Med. 2021;2021:1–9. doi:https://doi.org/10.1155/2021/9664195.
- Jin H-J, Kim J, Yu J. Androgen receptor genomic regulation. Transl Androl Urol. 2013;2(3):157–177. doi:https://doi.org/10.3978/j.2223-4683.2013.09.01.
- Bowman EP, Campbell JJ, Druey KM, Scheschonka A, Kehrl JH, Butcher EC. Regulation of Chemotactic and Proadhesive Responses to Chemoattractant Receptors by RGS (Regulator of G-protein Signaling) Family Members. J Biol Chem. 1998;273(43):28040–28048. doi:https://doi.org/10.1074/jbc.273.43.28040.
- Chatterjee TK, Fisher RA. Novel Alternative Splicing and Nuclear Localization of HumanRGS12 Gene Products. J Biol Chem. 2000;275(38):29660–29671. doi:https://doi.org/10.1074/jbc.M000330200.
- Heximer SP, Lim H, Bernard JL, Blumer KJ. Mechanisms Governing Subcellular Localization and Function of Human RGS2. J Biol Chem. 2001;276(17):14195–14203. doi:https://doi.org/10.1074/jbc.M009942200.
- Du WW, Yang W, Fang L, et al. miR-17 extends mouse lifespan by inhibiting senescence signaling mediated by MKP7. Cell Death Dis. 2014;5(7):e1355–e1355.doi:https://doi.org/10.1038/cddis.2014.305.
- Moreno-bueno G, Cubillo E, and Sarrio D, et al. Genetic Profiling of Epithelial Cells Expressing E-Cadherin Repressors Reveals a Distinct Role for Snail, Slug, and E47 Factors in Epithelial-Mesenchymal Transition. Cancer Res. 2020;6(20):9543–9556. doi:https://doi.org/10.1158/0008-5472.CAN-06-0479.
- Subramaniam S, Sreenivas P, Cheedipudi S, et al. Distinct Transcriptional Networks in Quiescent Myoblasts: a Role for Wnt Signaling in Reversible vs Irreversible Arrest. PLoS One. 2013. 8(6).DOI https://doi.org/10.1371/journal.pone.0065097.
- Aceto N, Bardia A, and Miyamoto DT, et al. NIH Public Access. Cell . 2015;158(5):1110–1122. doi:https://doi.org/10.1016/j.cell.2014.07.013.Circulating.
- Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget. 2016;7(29):46482–46491.doi:https://doi.org/10.18632/oncotarget.10208.
- Astvatsaturyan K, Yue Y, Walts AE, Bose S. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS One. 2018;13(6):e0197827. doi:https://doi.org/10.1371/journal.pone.0197827.
- Shen Y, Yang F, Zhang W, Song W, Liu Y, Guan X. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer. Cell Physiol Biochem. 2017;43(5):2047–2061. doi:https://doi.org/10.1159/000484187.
- Al-Othman N, Hammad H, Ahram M. Dihydrotestosterone regulates expression of CD44 via miR-328-3p in triple-negative breast cancer cells. Gene. 2018;675:128–135. doi:https://doi.org/10.1016/j.gene.2018.06.094.